Improving Outcomes in Pancreatic Adenocarcinoma: A Systematic Review of Immunotherapy in Multimodal Treatment

<i>Background</i>: Despite advances in chemotherapy and supportive care, pancreatic ductal adenocarcinoma (PDAC) continues to carry a dismal prognosis, with a five-year survival rate of approximately 13%. While immunotherapy has revolutionized treatment for several malignancies, its effi...

Full description

Saved in:
Bibliographic Details
Main Authors: Paul-Cristian Borz, Mihnea Bogdan Borz, Oliviu-Cristian Borz, Toader Zaharie, Claudia Hagiu, Lidia Munteanu, Simona Gurzu
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Medicina
Subjects:
Online Access:https://www.mdpi.com/1648-9144/61/6/1076
Tags: Add Tag
No Tags, Be the first to tag this record!